Mar 17 |
30 Biggest Biotechnology Companies in the World
|
Mar 15 |
Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares
|
Mar 12 |
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
|
Mar 6 |
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 6 |
Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
|
Feb 23 |
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
|
Feb 20 |
(BPMC) - Analyzing Blueprint Medicines's Short Interest
|
Feb 20 |
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
|
Feb 17 |
Blueprint Medicines Full Year 2023 Earnings: Beats Expectations
|
Feb 16 |
Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
|